Reversal of vasohibin-driven negative feedback loop of vascular endothelial growth factor/angiogenesis axis promises a novel antifibrotic therapeutic strategy for liver diseases
Potential conflict of interest: Nothing to report.
See Article on Page 633
This work was partially supported by a grant from the University Grant Commission Faculty Recharge Programme, Government of India (to S.C.).
No abstract is available for this article.